{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+withdrawal", "query": { "intervention": "Estradiol withdrawal" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+withdrawal&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T03:03:30.318Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00567164", "title": "Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Contraception", "Ovulation Inhibition", "Contraceptives, Oral" ], "interventions": [ { "name": "EE20/DRSP (BAY86-5300)", "type": "DRUG" }, { "name": "EE20/DRSP (YAZ, BAY86-5300)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 1887, "start_date": "2007-10", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2014-03-12", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567164" }, { "nct_id": "NCT02969590", "title": "Regulation of Cervical Mucus Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fertility", "Contraception" ], "interventions": [ { "name": "Leuprolide acetate", "type": "DRUG" }, { "name": "Estrogen and Progesterone Replacement", "type": "DRUG" }, { "name": "Progestin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "21 Years to 40 Years · Female only" }, "enrollment_count": 5, "start_date": "2015-03-29", "completion_date": "2017-08-23", "has_results": true, "last_update_posted_date": "2019-10-18", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02969590" }, { "nct_id": "NCT05230810", "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-08-25", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 4, "location_summary": "Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05230810" }, { "nct_id": "NCT03751124", "title": "Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uterine Leiomyoma", "Uterine Fibroids" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Placebo for relugolix", "type": "DRUG" }, { "name": "Placebo for E2/NETA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 229, "start_date": "2018-10-16", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03751124" }, { "nct_id": "NCT01165307", "title": "Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menorrhagia" ], "interventions": [ { "name": "Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills", "type": "DRUG" }, { "name": "Naproxen sodium pills", "type": "DRUG" }, { "name": "NovaSure® Radiofrequency Endometrial Ablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Abimbola Famuyide", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "30 Years to 55 Years · Female only" }, "enrollment_count": 77, "start_date": "2009-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165307" }, { "nct_id": "NCT03689543", "title": "Estrogen Receptor Beta and Mood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Perimenopause-Related Depression" ], "interventions": [ { "name": "Estradiol", "type": "DRUG" }, { "name": "ER Beta Agonist", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Provera", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "45 Years to 65 Years · Female only" }, "enrollment_count": 74, "start_date": "2019-05-23", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03689543" }, { "nct_id": "NCT06610305", "title": "Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Transdermal estradiol", "type": "DRUG" }, { "name": "Progesterone", "type": "DRUG" }, { "name": "Transdermal placebo patch", "type": "DRUG" }, { "name": "placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 75, "start_date": "2024-09-02", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06610305" }, { "nct_id": "NCT03047330", "title": "Menopausal Sleep Fragmentation and Body Fat Gain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menopause" ], "interventions": [ { "name": "Estradiol withdrawal", "type": "DRUG" }, { "name": "Fragmented sleep", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 41, "start_date": "2017-07-15", "completion_date": "2022-08-01", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03047330" }, { "nct_id": "NCT00089414", "title": "Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Premenstrual Syndrome", "PMS", "Premenstrual Dysphoric Disorder", "PMDD", "Depression" ], "interventions": [ { "name": "Ethinyl Estradiol/Drospirenone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "CDB 2914", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 5, "start_date": "2004-07", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2017-08-25", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089414" }, { "nct_id": "NCT05161195", "title": "Roll-over Study to Allow Continued Access to Ribociclib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 134, "start_date": "2022-07-07", "completion_date": "2030-08-14", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-11T03:03:30.318Z", "location_count": 16, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161195" } ] }